TY - JOUR
T1 - Possible factors in the potentiation of 1-(2-chloroethy)-3-trans-4-methylcyclohexyl-1-nitrosourea cytotoxicity by α-difluoromethylornithine in 9L rat brain tumor cells
AU - Oredsson, Stina M.
AU - Pegg, Anthony E.
AU - Alhonen-Hongisto, Leena
AU - Deen, Dennis F.
AU - Marton, Laurence J.
N1 - Funding Information:
Accepted 10 October 1983. *Supported by American Cancer Society Grant RD-137, NIH Program Project CA-13525, NIH Grant CA-18138, the Aaron Silvera Fund and travel grants (to S.M.O.) from the Swedish Natural Science Research Council (R-RA 4685-100) and the Swedish Medical Research Council (B81-04R-6065-504106065) and (to L. A-H.) from the National Research Council for Natural Sciences (Academy of Finland).
PY - 1984/4
Y1 - 1984/4
N2 - Depletion of intracellular levels of polyamines in 9L rat brain tumor cells by α -difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, significantly enhanced the cytotoxicity of 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl-1-nitrosourea (MeCCNU) in vitro as measured by a colony-forming efficiency assay. Administered as a single agent, DFMO was not cytotoxic to 9L cells. Treatment for 48 hr with 10, 1, 0.5 or 0.1 mM DFMO produced similar levels of polyamine depletion and similar potentiation of MeCCNU cytotoxicity. Restoration of intracellular polyamine levels by the addition of exogenous putrescine (1 mM) to treated cells prevented the potentiation of MeCCNU, which indicates that this phenomenon might be the result of polyamine depletion. DNA adduct formation in polyamine-depleted and control cell was studied with [14C]-MeCCNU; no difference in monoadduct formation was found between polyamine-depleted and control cells. Experiments to determine whether polyamine depletion has an effect on enzymes involved in the repair of alkylated bases showed that the activity of O6-methylguanine-DNA demethylase, 7-methylguanine-DNA glycosylase and 3-methyladenine-DNA glycosylace were unaffected by 48 hr of treatment with 10 mM DFMO. DFMO treatment causes a substantial increase in the intracellular content of decarboxylated S-adenosyl-l-methionine, which was reversed by addition of putrescine. The possibility that the elevation of decarboxylated S-adenosyl-l-methionine rather than the depletion of polyamines is responsible for the effects of DFMO is discussed.
AB - Depletion of intracellular levels of polyamines in 9L rat brain tumor cells by α -difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor of ornithine decarboxylase, significantly enhanced the cytotoxicity of 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl-1-nitrosourea (MeCCNU) in vitro as measured by a colony-forming efficiency assay. Administered as a single agent, DFMO was not cytotoxic to 9L cells. Treatment for 48 hr with 10, 1, 0.5 or 0.1 mM DFMO produced similar levels of polyamine depletion and similar potentiation of MeCCNU cytotoxicity. Restoration of intracellular polyamine levels by the addition of exogenous putrescine (1 mM) to treated cells prevented the potentiation of MeCCNU, which indicates that this phenomenon might be the result of polyamine depletion. DNA adduct formation in polyamine-depleted and control cell was studied with [14C]-MeCCNU; no difference in monoadduct formation was found between polyamine-depleted and control cells. Experiments to determine whether polyamine depletion has an effect on enzymes involved in the repair of alkylated bases showed that the activity of O6-methylguanine-DNA demethylase, 7-methylguanine-DNA glycosylase and 3-methyladenine-DNA glycosylace were unaffected by 48 hr of treatment with 10 mM DFMO. DFMO treatment causes a substantial increase in the intracellular content of decarboxylated S-adenosyl-l-methionine, which was reversed by addition of putrescine. The possibility that the elevation of decarboxylated S-adenosyl-l-methionine rather than the depletion of polyamines is responsible for the effects of DFMO is discussed.
UR - https://www.scopus.com/pages/publications/0021326314
UR - https://www.scopus.com/pages/publications/0021326314#tab=citedBy
U2 - 10.1016/0277-5379(84)90240-2
DO - 10.1016/0277-5379(84)90240-2
M3 - Article
C2 - 6426969
AN - SCOPUS:0021326314
SN - 0277-5379
VL - 20
SP - 535
EP - 542
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 4
ER -